ORCHESTRA BIOMED HOLDINGS INC.

NASDAQ: OBIO (Orchestra BioMed Holdings, Inc.)

Kemas kini terakhir: 46 minit lalu

6.97

-0.15 (-2.11%)

Penutupan Terdahulu 7.12
Jumlah Dagangan 551,845
Harga / Jualan (P/S) 14.70
Harga / Buku (P/B) 57.25
Julat 52 Minggu
3.46 (-50%) — 7.45 (6%)
Margin Operasi (TTM) -2,179.84%
EPS Cair (TTM) -1.77
Pertumbuhan Hasil Suku Tahunan (YOY) 40.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 97.55%
Nisbah Semasa (MRQ) 3.35
Aliran Tunai Operasi (OCF TTM) -54.06 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -28.16 M
Pulangan Atas Aset (ROA TTM) -60.70%
Pulangan Atas Ekuiti (ROE TTM) -179.12%

AISkor Stockmoo

0.5
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Aliran menaik sepanjang tahun lalu. Didagangkan hampir paras tertinggi 52 minggu. info
Harga dan purata bergeraknya tersusun dalam aliran menaik. Purata bergerak utamanya mendatar. Hampir dengan purata bergerak yang meningkat. Dagangan lebih tinggi pada hari harga naik. info
Corak Lilin info NA
Di atas garis aliran jangka sederhana. info
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini bercampur atau neutral. info
Beberapa orang dalam membeli bersih baru-baru ini. info
Institusi bersih +5.72% daripada saham dalam pemfailan 13F terkini: 61 pemegang menambah, 31 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +11.0% dari 31 Aug hingga 30 Oct 2026, 7 hari untuk tutup (FINRA). info
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak tidak sependapat, jadi skor dilemahkan.
Harga tinggi berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Aliran naik bagi ketiga-tiga tempoh. Momentum jangka pendek meningkat. info
Tiada isyarat jelas daripada sokongan dan rintangan. info
Skor Akhir 0.53
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Orchestra BioMed Holdings, Inc. Bercampur Menurun

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
OBIO - - - 57.25
TRML 1 B - - 4.76
VRDN - - - 7.26
VRCA - - - 15.60
TECH - 0.44% - 5.28
ABEO - - - 1.10

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 21.81%
% Dimiliki oleh Institusi 49.62%
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
FAIN ERIC S 5.70 - 20,000 114,000
HOCHMAN DAVID P 5.70 - 5,000 28,500
PACITTI DAVID 5.70 - 20,000 114,000
TAYLOR ANDREW LAWRENCE 5.70 - 1,000 5,700
Jumlah Keseluruhan Kuantiti Bersih 46,000
Jumlah Keseluruhan Nilai Bersih ($) 262,200
Purata Pembelian Keseluruhan ($) 5.70
Purata Jualan Keseluruhan ($) -
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
TAYLOR ANDREW LAWRENCE Pegawai 09 Nov 2026 Beli (+) 1,000 5.70 5,700
HOCHMAN DAVID P Pegawai 09 Nov 2026 Beli (+) 5,000 5.70 28,500
PACITTI DAVID Pengarah 09 Nov 2026 Beli (+) 20,000 5.70 114,000
FAIN ERIC S Pengarah 09 Nov 2026 Beli (+) 20,000 5.70 114,000

Institusi

Pemilikan institusi: 41.73%

Kedudukan Pemegang Saham
Bertambah 61 5,034,559
Berkurang 31 1,386,397
Baharu 27 1,437,879
Dijual habis 11 569,836

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 2,732,484 7.0
15 Oct 2026 2,552,988 9.7
30 Sep 2026 2,547,249 7.0
15 Sep 2026 2,372,557 6.6
31 Aug 2026 2,460,669 5.8
14 Aug 2026 2,383,854 13.1

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

2 Positif 3 Negatif 1 Neutral
Tarikh Jenis Butiran
17 Nov 2026 Yahoo Finance Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device…
16 Nov 2026 Yahoo Finance Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
The mean of analysts' price targets for Orchestra BioMed Holdings, Inc. (OBIO) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
10 Nov 2026 Yahoo Finance Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +25.00% and -17.27%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
10 Nov 2026 Yahoo Finance Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized.BACKBEAT Trial primary endpoint data planned to be submitted for late-breaking presentation at the Heart Rhythm Society 2027 (“HRS 2027”).Medtronic…
05 Nov 2026 Yahoo Finance Orchestra BioMed Announces Pricing of Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device…
05 Nov 2026 Yahoo Finance Orchestra BioMed Announces Proposed Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device…
29 Oct 2026 Yahoo Finance Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels…
22 Oct 2026 Yahoo Finance Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq…
20 Oct 2026 Yahoo Finance OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .
01 Oct 2026 Yahoo Finance Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
330 patients randomized as of September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing…
21 Sep 2026 Yahoo Finance Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
16 Sep 2026 Yahoo Finance Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyondNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO)…
15 Sep 2026 Yahoo Finance Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds through future revenue earnoutsMonetization of a strategic holding provides…
02 Sep 2026 Yahoo Finance Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported…
27 Aug 2026 Yahoo Finance Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman…
20 Aug 2026 Yahoo Finance Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman…
Papar semua

Isyarat Terkini corak lilin dan silang EMA

▲ Silang EMA menaik 4 sesi lalu · 11 Nov
Jangka pendek · EMA 7/20
EMA 7 hari melintas ke atas EMA 20 hari: momentum jangka pendek berubah menaik.

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Harga dan purata bergeraknya tersusun dalam aliran menaik. Purata bergerak utamanya mendatar. Hampir dengan purata bergerak yang meningkat. Dagangan lebih tinggi pada hari harga naik.
Sokongan terdekat: 6.36 – 6.62 · paras kukuh

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda